ES2187972T3 - Metodos para la modulacion del crecimiento de arterias colaterales y/u otras arterias a partir de conexiones arteriolares preexistentes. - Google Patents

Metodos para la modulacion del crecimiento de arterias colaterales y/u otras arterias a partir de conexiones arteriolares preexistentes.

Info

Publication number
ES2187972T3
ES2187972T3 ES98924093T ES98924093T ES2187972T3 ES 2187972 T3 ES2187972 T3 ES 2187972T3 ES 98924093 T ES98924093 T ES 98924093T ES 98924093 T ES98924093 T ES 98924093T ES 2187972 T3 ES2187972 T3 ES 2187972T3
Authority
ES
Spain
Prior art keywords
arteries
growth
connections
methods
collateral
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES98924093T
Other languages
English (en)
Inventor
Wolfgang Schaper
Wulf D Ito
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Max Planck Gesellschaft zur Foerderung der Wissenschaften eV
Original Assignee
Max Planck Gesellschaft zur Foerderung der Wissenschaften eV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Max Planck Gesellschaft zur Foerderung der Wissenschaften eV filed Critical Max Planck Gesellschaft zur Foerderung der Wissenschaften eV
Application granted granted Critical
Publication of ES2187972T3 publication Critical patent/ES2187972T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/195—Chemokines, e.g. RANTES
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Liquid Crystal Display Device Control (AREA)
  • Measurement And Recording Of Electrical Phenomena And Electrical Characteristics Of The Living Body (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Se describe la modulación del crecimiento de arterias colaterales u otras arterias de conexiones arteriolares preexistentes. Se proporcionan procedimientos para intensificar el crecimiento de arterias colaterales u otras arterias de conexiones arteriolares preexistentes que contienen tejido de contacto o células con una proteína de monocito químicamente activa (MCP) o una molécula de ácido nucleico que codifique dicha MCP. También se describe el uso de una MCP o de una molécula de ácido nucleico que codifique dicha MCP para la preparación de composiciones farmacéuticas para intensificar el crecimiento colateral de arterias colaterales u otras arterias de conexiones arteriolares preexistentes. También se proporcionan procedimientos para el tratamiento de tumores que comprenden tejido de contacto o células con un agente supresor del crecimiento de arterias colaterales u otras arterias de conexiones arteriolares preexistentes mediante atracción de monocitos. También se describe la utilizaciónde un agente supresor del crecimiento de arterias colaterales u otras arterias de conexiones arteriolares preexistentes mediante atracción de monocitos para la preparación de composiciones farmacéuticas para el tratamiento de tumores.
ES98924093T 1997-04-04 1998-04-01 Metodos para la modulacion del crecimiento de arterias colaterales y/u otras arterias a partir de conexiones arteriolares preexistentes. Expired - Lifetime ES2187972T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP97105647 1997-04-04

Publications (1)

Publication Number Publication Date
ES2187972T3 true ES2187972T3 (es) 2003-06-16

Family

ID=8226664

Family Applications (1)

Application Number Title Priority Date Filing Date
ES98924093T Expired - Lifetime ES2187972T3 (es) 1997-04-04 1998-04-01 Metodos para la modulacion del crecimiento de arterias colaterales y/u otras arterias a partir de conexiones arteriolares preexistentes.

Country Status (10)

Country Link
US (2) US6592862B1 (es)
EP (2) EP0969877B1 (es)
JP (1) JP2001519795A (es)
AT (1) ATE232399T1 (es)
CA (1) CA2284922A1 (es)
DE (1) DE69811348T2 (es)
DK (1) DK0969877T3 (es)
ES (1) ES2187972T3 (es)
PT (1) PT969877E (es)
WO (1) WO1998044953A1 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6528625B1 (en) 1996-10-28 2003-03-04 Millennium Pharmaceuticals, Inc. Anti-CCR5 antibodies and kits comprising same
DE69821011T3 (de) * 1997-10-02 2009-01-08 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Verfahren zur Modulierung der Neovaskularisierung und/oder des Wachstums kollateraler Arterien und/oder anderer Arterien aus bestehenden arteriolären Verbindungen
US6749617B1 (en) 1997-11-04 2004-06-15 Scimed Life Systems, Inc. Catheter and implants for the delivery of therapeutic agents to tissues
US6696550B2 (en) 1998-07-23 2004-02-24 Millennium Pharmaceuticals, Inc. Humanized anti-CCR2 antibodies and methods of use therefor
US6312689B1 (en) 1998-07-23 2001-11-06 Millennium Pharmaceuticals, Inc. Anti-CCR2 antibodies and methods of use therefor
US6727349B1 (en) 1998-07-23 2004-04-27 Millennium Pharmaceuticals, Inc. Recombinant anti-CCR2 antibodies and methods of use therefor
US6488930B1 (en) 1999-01-15 2002-12-03 Millennium Pharmaceuticals, Inc. Anti-CCR4 antibodies and methods of use therefor
US6245332B1 (en) 1999-01-15 2001-06-12 The Board Of Trustees Of The Leland Stanford Junior University Modulation of systemic memory T cell trafficking
US6329510B1 (en) 1999-01-29 2001-12-11 Millennium Pharmaceuticals, Inc. Anti-CCR1 antibodies and methods of use therefor
WO2000060054A1 (en) * 1999-04-06 2000-10-12 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Pharmaceutical compositions comprising circulating blood cells, preferably monocytes and uses thereof
US20020034501A1 (en) * 2000-05-18 2002-03-21 Robert Pawliuk Methods and compositions for promoting angiogenesis using monocytes
WO2001089565A1 (en) * 2000-05-19 2001-11-29 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods for reducing tumor growth and metastasis by inhibiting mcp-1 activity
DE60142584D1 (de) * 2000-11-08 2010-08-26 Boston Scient Ltd Multilumen katheter und implantate zur verabreichung von therapeutischen substanzen an gewebe
US10590418B2 (en) 2001-07-23 2020-03-17 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for RNAi mediated inhibition of gene expression in mammals
ES2546829T3 (es) * 2001-07-23 2015-09-29 The Board Of Trustees Of The Leland Stanford Junior University Métodos y composiciones para la inhibición mediada por iARN de la expresión génica en mamíferos
US20040151721A1 (en) 2001-10-19 2004-08-05 O'keefe Theresa Humanized anti-CCR2 antibodies and methods of use therefor

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5179078A (en) * 1989-05-12 1993-01-12 Dana Farber Cancer Institute Method of suppressing tumor formation in vivo
WO1995031467A1 (en) * 1994-05-16 1995-11-23 Human Genome Sciences, Inc. Monocyte chemotactic protein-4
EA001616B1 (ru) * 1995-02-28 2001-06-25 Зе Риджентс Оф Зи Юнивесити Оф Кэлифоньэ Способ лечения болезни сердца, способ лечения недостаточности периферических сосудов и способ ограничения доставки и экспрессии трансгенной конструкции в определенном органе или структуре
US6544543B1 (en) * 2000-12-27 2003-04-08 Advanced Cardiovascular Systems, Inc. Periodic constriction of vessels to treat ischemic tissue

Also Published As

Publication number Publication date
DE69811348T2 (de) 2003-12-24
DK0969877T3 (da) 2003-03-24
WO1998044953A1 (en) 1998-10-15
EP0969877A1 (en) 2000-01-12
ATE232399T1 (de) 2003-02-15
US6592862B1 (en) 2003-07-15
US20040023881A1 (en) 2004-02-05
CA2284922A1 (en) 1998-10-15
EP1304123A3 (en) 2003-11-19
EP1304123A2 (en) 2003-04-23
PT969877E (pt) 2003-06-30
EP0969877B1 (en) 2003-02-12
DE69811348D1 (de) 2003-03-20
JP2001519795A (ja) 2001-10-23

Similar Documents

Publication Publication Date Title
ES2187972T3 (es) Metodos para la modulacion del crecimiento de arterias colaterales y/u otras arterias a partir de conexiones arteriolares preexistentes.
ATE375401T1 (de) Vaccinia virus für diagnose und behandlung von tumoren
DK1019082T3 (da) Fremgangsmåde til moduleringen af neovaskularisering og/eller væksten af kollaterale arterier og/eller andre arterier fra forudeksisterende arteriolære forbindelser
EA200000445A1 (ru) Способы лечения состояния гиперкоагуляции или приобретенной недостаточности белка c
EA199801044A1 (ru) Модуляторы регенерации тканей
BG101103A (bg) Теломераза при бозайници
EP1832599A3 (en) Albumin fusion proteins
TW428026B (en) Bifunctional protein, preparation and use
BR9812096A (pt) Proteìna receptora/ligante solúvel interleucina-6 quimérica, seus análogos e seus usos
NO993709D0 (no) Stabilisert blanding omfattende fibrinogen
BR0206985A (pt) Anticorpos modificados e métodos de uso
DE69739675D1 (de) Oter
EP1090924A4 (en) TUMORANTIGEN PEPTIDES DERIVED FROM CYCLOPHILIN B.
BR9811094A (pt) Agente terapêutico para tumores linfáticos
SE8902532L (sv) Bestaemning av plasmaproteiner
EA200401111A1 (ru) Биполярные соли транс-каротиноидов и их применение
NO971341L (no) Promoter for reseptor tyrosinkinase TIE
DE69910809D1 (de) Verwendung von OmpA Enterobakterproteinen um zielgerichtet Antigen-Präsentierende Zellen anzusteuern
DE59709856D1 (de) Konjugat aus albumin und einem xanthen-farbstoff zur unterscheidung von krankhaftem und gesundem gewebe
BR9811907A (pt) Proteìna de ligação de lactoferrina de neisseria
DE69636041D1 (de) Nachweis von brusttumorvirus-artigen sequenzen in brustkrebs bei menschen
DE69929683D1 (de) Antisense modulierung von lfa-3
DE3883044D1 (de) Wirkstoff zur tumorbekaempfung.
ATE323719T1 (de) Hla-a2 beschränktes tumorantigen-peptid, das von sart-1 abstammt
NO20005321L (no) Vertskodet protein uttrykt i Mareks sykdoms (MDV) infiserte celler og antistoffer til dette